About us
NuVision® is an expert team of scientific, clinical and industry professionals dedicated to building innovative ocular biotherapies. Our work is rooted in our values.
NuVision was founded in 2015 based on 15 years of translational research at the University of Nottingham. Research and innovation are still at our core as we continue to develop new technologies. We’re building our portfolio of ocular biotherapies to ensure no patient goes without immediate access to treatment.
Meet the team
Roger Teasdale
Chairman
Roger joined as Independent Non-Executive Director in 2018 and transitioned into the Chairman role in 2024. Roger has a track record of driving revenue and profit in the medical device industry.
He enjoyed a 25 year long career at Smith & Nephew – a FTSE 100 medical device business focused on Advanced Wound Management and Advanced Surgical Devices with sales exceeding $4.8 billion and operations in 120 countries. During this time, he was President of the Global Advanced Wound Management business with sales of $1.4 billion, overseeing 4,000 people in 80 countries. Most recently he was Group Managing Director at the Premier Technical Services Group. Roger holds a BA in Accounting and Management Control and is a Chartered Accountant.
Noel Waters
Chief Operating Officer
Noel has over 35 years’ experience establishing highly successful manufacturing and supply chain operations from concept to execution, in multiple regions including both China and India.
Additionally, he has lead M&A initiatives, and has devised and implemented global enterprise resource planning (ERP) system strategy. Noel joins NuVision following significant achievement in major global manufacturing businesses, previously working for Smith & Nephew PLC as their Senior Vice President AWM Global Operations. Most recently, Noel has become both the Proprietor and Director of HTNW Limited, an Interim Operations Management and Consultancy focused on the medical device sector.
Tim Gray
Chief Financial Officer
Tim is a seasoned finance professional with over 20 years of experience in private equity backed companies, delivering strong commercial and financial leadership at Board level.
Tim has demonstrated expertise in cost management, cash control, and business reporting to drive improved bottom-line results. Skilled at collaborating across internal teams and with external stakeholders, and equally effective in environments of high growth, transformation, turnaround, or steady-state operations within international commercial organisations.
Dr. Andrew Hopkinson
Chief Scientific Officer
Andrew is the founder of NuVision with over 15 years’ experience in translational ophthalmic academic research at the University of Nottingham Ophthalmology department.
Andrew remains an honorary senior academic with the University and together with the multidisciplinary research team at the University of Nottingham, he continues developing innovative technologies to repair and regenerate the ocular surface. This research pioneered the development of Tereo® processing and Omnigen. He continues to research in this area, fuelling the future of innovative biotherapies for NuVision.
Tonicha Spencer
Head of UK Sales and Clinical Support
Tonicha leads our UK sales, marketing and communication strategy, working closely with NHS partners and healthcare organisations across the country.
Originally trained as a medicinal chemist, Tonicha combines scientific expertise with a deep understanding of commercial needs to deliver effective, evidence-based solutions that support better patient outcomes. Drawing on a strong technical foundation and years of experience in the healthcare sector, Tonicha ensures our products and services are communicated clearly, ethically, and with real-world impact.
Mr. Dushyant Mital
Medical Advisor
Dush joined in 2020 as a Medical Advisor bringing in over 27 years of experience as a Clinician, Researcher, Educator and Executive Director in the NHS.
Dush began his career with a Medical Degree from St George’s Hospital Medical School, University of London and is currently an NHS consultant in Blood Bourne Viruses at Milton Keynes University Hospital and Clinical Lecturer at the University of Buckingham Medical School. He is also Regional Lead for Infectious Diseases & Microbiology for the National Institute of Healthcare Research (NIHR) and is currently a principal investigator for several COVID-19 and HIV related clinical trials. He has over 50 publications and abstracts in his area of medical expertise.